Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on October 16, 2024. The document announced that NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g), was not withdrawn from sale for reasons of safety or effectiveness. The document incorrectly listed the dosage strength as 100 g. The correct strength is 100 milligrams (mg). This notice corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 224 (Wednesday, November 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Page 91757]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-27082]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-P-4163]
Determination That NOXAFIL (Posaconazole) Delayed-Release
Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on October 16, 2024. The document
announced that NOXAFIL (posaconazole) delayed-release tablets, 100
grams (g), was not withdrawn from sale for reasons of safety or
effectiveness. The document incorrectly listed the dosage strength as
100 g. The correct strength is 100 milligrams (mg). This notice
corrects that error.
FOR FURTHER INFORMATION CONTACT: Awo Archampong-Gray, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6243, Silver Spring, MD 20993-0002, 301-
796-0110, <a href="/cdn-cgi/l/email-protection#0140766e2f40736269606c716e6f662c46736078416765602f6969722f666e77"><span class="__cf_email__" data-cfemail="4b0a3c24650a3928232a263b24252c660c392a320b2d2f2a65232338652c243d">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In FR Doc. 2024-23811, published in the
Federal Register of Wednesday, October 16, 2024 (89 FR 83504),
appearing on pages 83504 and 83505, the following corrections are made:
1. On page 83504, in the second column, the title of the document
is corrected to read ``Determination That NOXAFIL (Posaconazole)
Delayed-Release Tablets, 100 Milligrams, Was Not Withdrawn From Sale
for Reasons of Safety or Effectiveness.''
2. On page 83504, in the third column, in the SUMMARY, in the first
paragraph, ``NOXAFIL (posaconazole) delayed-release tablets, 100 grams
(g),'' is corrected to read ``NOXAFIL (posaconazole) delayed-release
tablets, 100 milligrams (mg),''.
3. On page 83505, in the first and second columns, all uses of
``100 g'' are corrected to read ``100 mg''.
Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2024-27082 Filed 11-19-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.